Saturday, biopharmaceutical company Allos Therapeutics, Inc. (ALTH)reported new analysis of data from pivotal PROPEL trial of FOLOTYN or pralatrexate injection in patients with relapsed or refractory peripheral T-cell lymphoma or PTCL.
The company indicated that treatment with FOLOTYN achieved an overall response rate of 29% (32 of 109 evaluable patients). Sixty-three percent of patients responded within the first cycle of therapy. Responses were durable with a median duration of response of 10.1 months. Median overall survival was 14.5 months.
"FOLOTYN is an important new therapy for patients with relapsed or refractory PTCL and for physicians who treat patients afflicted with this very aggressive cancer," said Owen O'Connor, principal investigator in the PROPEL study of FOLOTYN.
The Westminster, Colorado-based company said FOLOTYN is the first and only drug approved by the U.S. Food And Drug Administration for this indication and represents a new treatment option for patients with relapsed or refractory PTCL. FOLOTYN has been available to patients in the U.S. since October 2009.
ALTH closed Friday's regular trading at $6.62, up $0.16 or 2.48%, on a volume of about 1.39 million shares. In the after hours, the stock further gained $0.12 or 1.81% and traded at $6.74.
For comments and feedback: editorial@rttnews.com